<a href="https://laohu8.com/S/URGN">UroGen</a> Pharma Announces Positive Clinical Results for ZUSDURI™ in Recurrent Low-Grade, Intermediate-Risk Non-Muscle Invasive Bladder Cancer
UroGen Pharma Ltd. has announced the publication of a comprehensive clinical review of ZUSDURI™ (mitomycin) for intravesical solution, the first and only FDA-approved medication for adults with recurrent, low-grade, intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC). The review, published in the peer-reviewed journal *Reviews in Urology™*, summarizes data from three late-phase clinical trials-OPTIMA II, ATLAS, and ENVISION-evaluating the safety and efficacy of ZUSDURI in this patient population. Results from these studies have already been presented and indicate complete response rates between 64.8% and 79.6% at three months. ZUSDURI is administered as a non-surgical, outpatient treatment and is reported to have a safety profile manageable in routine urologic practice.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Urogen Pharma Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9538923-en) on October 02, 2025, and is solely responsible for the information contained therein.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。